http://www.nejm.org/doi/full/10.1056/NEJMp1601294?utm_campaign=KHN%3A+Daily+Health+Policy+Report&utm_source=hs_email&utm_medium=email&utm_content=29514168&_hsenc=p2ANqtz-_mhuZY8I1CwE2JaU7KXf7klesY9p7YngvovjjsHKAbNVfnE2nViv1V8f1h8S0PR5h41XLpae3XGq5fFQ5NnvEuAJ0UEw&_hsmi=29514168&

Public debate in the 1990s over drugs’ clinical toxicity has given way to concerns about their financial toxicity. Although drug regulators aren’t supposed to be concerned with pricing, they’ve been drawn into an acrimonious debate over the cost of medicines.